Form 8-K - Current report:
SEC Accession No. 0001641172-25-008365
Filing Date
2025-05-02
Accepted
2025-05-02 16:30:13
Documents
15
Period of Report
2025-04-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47682
2 EX-16.1 ex16-1.htm EX-16.1 4970
  Complete submission text file 0001641172-25-008365.txt   280719

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cldi-20250430.xsd EX-101.SCH 3813
4 XBRL DEFINITION FILE cldi-20250430_def.xml EX-101.DEF 30090
5 XBRL LABEL FILE cldi-20250430_lab.xml EX-101.LAB 36817
6 XBRL PRESENTATION FILE cldi-20250430_pre.xml EX-101.PRE 27113
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5801
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 25909084
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)